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ABSTRACT
Introduction: 2018 World Health Organization (WHO) guidelines for the treatment of isoniazid
(H)-resistant (Hr) tuberculosis recommend a four-drug regimen: rifampicin (R), ethambutol (E),
pyrazinamide (Z) and levofloxacin (Lfx), with or without H ([H]RZE-Lfx). This is used once Hr is known,
such that patients complete 6 months of Lfx (⩾6[H]RZE-6Lfx). This cohort study assessed the impact of
fluoroquinolones (Fq) on treatment effectiveness, accounting for Hr mutations and degree of phenotypic
resistance.
Methods: This was a retrospective cohort study of 626 Hr tuberculosis patients notified in London, 2009–
2013. Regimens were described and logistic regression undertaken of the association between regimen and
negative regimen-specific outcomes (broadly, death due to tuberculosis, treatment failure or disease
recurrence).
Results: Of 594 individuals with regimen information, 330 (55.6%) were treated with (H)RfZE
(Rf=rifamycins) and 211 (35.5%) with (H)RfZE-Fq. The median overall treatment period was 11.9 months
and median Z duration 2.1 months. In a univariable logistic regression model comparing (H)RfZE with
and without Fqs, there was no difference in the odds of a negative regimen-specific outcome (baseline (H)
RfZE, cluster-specific odds ratio 1.05 (95% CI 0.60–1.82), p=0.87; cluster NHS trust). Results varied
minimally in a multivariable model. This odds ratio dropped (0.57, 95% CI 0.14–2.28) when Hr genotype
was included, but this analysis lacked power (p=0.42).
Conclusions: In a high-income setting, we found a 12-month (H)RfZE regimen with a short Z duration to
be similarly effective for Hr tuberculosis with or without a Fq. This regimen may result in fewer adverse
events than the WHO recommendations.
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Introduction
Isoniazid (H) is a key drug used in the treatment of both tuberculosis disease (TB) and latent TB infections.
Research into H-resistant (Hr) TB has been neglected in favour of studies of simultaneous Hr and rifampicin
(R) resistance (Rr), i.e. multidrug resistance (MDR) [1]. Globally, 7.1% of new incident TB patients between
2003 and 2017 had Hr disease without associated Rr (henceforth known as “Hr TB”), as did 7.9% of
previously treated patients [2]. The distribution of Hr TB varies substantially by country [1, 3].
Hr has been associated with poor treatment outcomes, the need to tailor treatment regimens and the
development of additional drug resistance during treatment [1]. A meta-analysis of randomised controlled
trial (RCT) data, controlling for regimen, demonstrated that incidence rates of treatment failure were
10.9 times higher in Hr TB versus drug-sensitive disease (95% CI 5.9–20) [4]. In the same study, relapse
rates in Hr TB were 1.8-fold higher (1.2–2.6) and acquired drug resistance 5.1 times higher (2.3–11.0).
Given these concerns, policymakers have issued specific treatment guidance for Hr TB. In 2018 the World
Health Organization (WHO) conditionally recommended a regimen of R, ethambutol (E), pyrazinamide
(Z) and levofloxacin (Lfx) with or without H ([H]RZE-Lfx), to be initiated once Hr is confirmed [5]. If
treatment starts before Hr is known, it is continued until Lfx is used for 6 months, even if the duration of
the other drugs is therefore longer (⩾6[H]RZE-6Lfx). In the absence of rapid molecular testing for Hr,
overall treatment duration is thus 7.5–9 months, depending upon whether liquid or solid culture is used
[6]. WHO has assessed the evidence underlying this regimen to be of very low certainty [5]. Within the
UK, the National Institute for Health and Care Excellence recommends a 9-month regimen of 2 months
of RZE, followed by 7 months of RE [7]. This can be extended to 12 months’ duration (10-month
continuation phase), if disease is extensive. The American Thoracic Society is currently revising its
guidance [8]. In 2003, they recommended a 6-month regimen of RZE, plus a fluoroquinolone (Fq) for
extensive disease [9]. All bodies acknowledge the need for future studies to optimise regimens, e.g. to
determine the implications of the resistance-causing Hr mutation(s).
In light of the 2018 WHO recommendations, we undertook a retrospective cohort study to identify the
treatment regimens currently being used for Hr TB in a high-income setting with universal healthcare
(London, UK). We assessed the importance of including Fqs during treatment, accounting for baseline
Hr phenotype and genotype.
Methods
Study population
We included all patients aged ⩾18 years notified in England (as a statutory requirement) to Public Health
England (PHE)’s Enhanced TB Surveillance system (ETS) between January 1, 2009 and December 31,
2013 with disease caused by phenotypically Hr Mycobacterium tuberculosis. Baseline demographic and
basic clinical and microbiological data were available from PHE. Individuals notified in London formed
the retrospective cohort; additional data collection for these individuals is described below.
Treatment regimens
Detailed regimen, adherence and regimen-specific outcome information was gathered from clinical notes
at the last hospital to treat the patient recorded by PHE (supplementary file 1).
Affiliations: 1Institute for Global Health, University College London, London, UK. 2Usher Institute of
Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK. 3Respiratory Medicine,
Homerton University Hospital, London, UK. 4Tuberculosis Unit, National Infection Service, Public Health
England, London, UK. 5Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary
University of London, London, UK. 6Respiratory Medicine, Royal Free Hospital, London, UK. 7UCL Respiratory,
Division of Medicine, University College London. 8Respiratory Medicine, North Middlesex University Hospital,
London, UK. 9Infectious Diseases, London North West University Healthcare NHS Trust, London, UK.
10National Mycobacterial Reference Service South, Public Health England, London, UK. 11Tuberculosis
Service, University College London Hospitals/Whittington Health, London, UK. 12Respiratory Medicine, Barnet
General Hospital, Royal Free London NHS Foundation Trust, London, UK. 13Statistics, Modelling and
Economics Department, Public Health England, London, UK. 14TB Service, Imperial College Healthcare,
London, UK. 15Respiratory Medicine, Chelsea and Westminster Hospital, London, UK. 16Centre for Clinical
Microbiology, University College London, London, UK. 17Respiratory Medicine, Guy’s and St Thomas’ Hospital,
London, UK. 18Respiratory Services, Queen Elizabeth Hospital, London, UK. 19Dept of Medicine and Dept of
Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA. 20Additional
London INH-R TB study group members are listed in the acknowledgements section. 21These authors
contributed equally to this manuscript and are presented alphabetically. 22These authors contributed equally
to this manuscript and are presented alphabetically.
Correspondence: Helen R. Stagg, Usher Institute of Population Health Sciences and Informatics, University of
Edinburgh, Edinburgh, EH8 9DX, UK. E-mail: helen.stagg@ed.ac.uk
https://doi.org/10.1183/13993003.00982-2019 2
TUBERCULOSIS | H.R. STAGG ET AL.
Regimens were described and categorised. The rifamycins (Rf) R and rifabutin were grouped together, as
were the injectables, Fqs other than moxifloxacin (M), and the previously named group 4/5 drugs [10, 11].
A binary regimen variable was created of RfZE regimens in the presence or absence of H with or without
an additional Fq: (H)RZE versus (H)RZE-Fq/M. If additional drugs were included, the regimen was not
counted within the binary variable.
The presence of high-dose H within the regimen was documented, as was whether Rf, Z or E were dosed
thrice weekly (as opposed to more frequently). The length of time a patient was treated before the regimen
was adapted to account for Hr (which was dependent on the duration of drug sensitivity testing (DST))
was grouped 0 to <2, 2 to <6 and ⩾6 months.
Genotyping and phenotyping
Phenotypic DSTs for first-line drugs were conducted on baseline samples. DSTs for second-line drugs
were conducted if resistance to R or two or more other first-line drugs (but not H alone, although this
could be requested) was detected. These results were recorded within ETS. Patients were grouped
according to the baseline drug resistance pattern of their disease.
The degree of phenotypic resistance to H was extracted from the National Mycobacterium Reference
Service (NMRS)-South system (supplementary file 1).
Whole-genome sequencing (WGS) to detect resistance mutations was undertaken for a subset of patients
among those notified 2012–2013 using an Illumina HiSeq (San Diego, CA, USA) at the PHE central
sequencing unit [12].
Other exposure variables
Age, sex, being born in the UK, ethnic group, social risk factors (homelessness, problematic drug use,
problematic alcohol use and imprisonment), previous diagnosis of TB and inpatient information came
from ETS. Decisions surrounding the grouping of these variables are documented in supplementary file 1.
An outbreak of Hr TB has been present in (mainly north) London since 1995 [13, 14]. Due to awareness
of this outbreak among clinicians, patients with epidemiological risk factors consistent with the outbreak
(in which nonadherence was common and treatment outcomes poor) may have been treated differently
from other patients.
An additional variable documented if a patient had issues adhering to treatment, according to their clinical
notes (supplementary file 1).
Outcomes
A patient’s treatment period for Hr TB is made up of up to three components: the regimen used prior to
Hr being known; the regimen used once Hr is known; and (potentially) a further regimen or regimens if
the Hr regimen is insufficiently effective. Overall treatment outcomes (available in ETS) capture this entire
period. Regimen-specific outcomes, taken from clinical notes, document the effectiveness of the Hr
regimen and thus capture only the first two components (table 1). For the regression model, the neutral
and positive groups were merged to create a binary outcome.
Analysis
Data were cleaned in Microsoft Excel (Redmond, WA, USA) and analysed in Stata 15 (StataCorp, College
Station, TX, USA).
The characteristics of the London cohort were assessed. Descriptive analyses of the regimens used were
undertaken, followed by regression analyses. Initially, individuals with additional phenotypic drug
resistance identified in baseline samples taken were excluded from the regression models, unless resistance
was to streptomycin (S). This was because S is not routinely used in the treatment of drug-sensitive or
MDR TB in the UK [7, 16]. Random-effects univariable logistic regression models were built to examine
the impact of different factors on the likelihood of negative regimen-specific outcomes, with a random
effect included on National Health Service (NHS) trust to adjust for clustering.
A multivariable logistic regression model was then built, using the binary regimen categorisation as the
main exposure and including a random effect on NHS trust. Details of confounder selection, etc. are
presented in supplementary file 1.
Sensitivity and extended analyses
Four additional logistic regression models were run. The first included Hr genotyping results. Next,
adherence was substituted for thrice-weekly dosing. The third included all patients, regardless of whether
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they were resistant to drugs in addition to H (and S). The fourth was a post hoc model adjusting for
factors associated with the use of Fqs.
Ethical permissions
PHE is legislated by the National Information Governance Board for Health and Social Care to hold and
analyse surveillance data for public health purposes under section 251 of the NHS Act 2006. This
retrospective cohort study was approved by the London Camberwell St Giles research ethics committee
(16/LO/1269) and, in addition, given permission to undertake data extraction without consent under
section 251 (Confidentiality Advisory Group reference 16/CAG/0092).
TABLE 1 Classification of regimen-specific outcomes
Components Comments
Negative Treatment completed, followed by recurrence; outcome missing,
but recurrence; or neutral outcome, followed by recurrence
Recurrence of disease ⩾12 months after notification;
recurrences documented until the end of 2015 (the most
recent available data at the time of analysis); if disease
recurred after the end of treatment at any time and the
patient re-presented to the same hospital, this was classified
as a negative outcome
Died due to TB or TB-associated death ⩾2 weeks after starting
treatment
Death before 2-week threshold considered to be too early to be
influenced by the treatment [15]
Treatment stopped early or regimen changed due to worsening/
not improving, treatment failure, adverse events or the
development of additional drug resistance
Length extended, antibiotics added/removed, frequency altered,
dose altered, treatment stopped
Additional drug resistance developed during treatment To any drug
Neutral Died from TB or TB-associated death within 2 weeks of starting
treatment
Death before 2-week threshold considered to be too early to be
influenced by the treatment [15]
Died from non-TB related causes, or cause unknown
Treatment stopped early or regimen changed due to
non-adherence, loss to follow-up, patient choosing to cease
their medication, pregnancy or comorbidities
Patient transferred to another hospital during their treatment No further documentation; transfer before any negative
outcomes occurred
Positive Treatment completed as initially prescribed (once Hr known); or
treatment completed, no recurrence
Regimen-specific outcomes (extracted from clinical notes) presented in detail. The first outcome arising per patient was documented, unless a
negative outcome occurred after one that is neutral. TB: tuberculosis; Hr: isoniazid resistance.
FIGURE 1 Flow chart of participants.
Hr: isoniazid-resistant; TB: tuber-
culosis; PHE: Public Health England.
n=1228 Hr TB patients notified to PHE 2009–2013
n=601 non-London
One hospital had a single patient
n=627 notified by London hospitals
n=626 notified by London hospitals that were 
approached
n=592 patients with regimen-specific outcomes
n=594 patients with treatment regimen data
n=579 degree of phenotypic resistance known
n=171 genotyping results
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Results
Patient population
1228 individuals with Hr TB were notified in England between 2009 and 2013 (figure 1). Of these,
626 (51.0%) were notified by 31 hospitals (supplementary file 2) in London (19 NHS trusts). One hospital
TABLE 2 Demographic and clinical baseline characteristics of the 626 individuals in the
London cohort
Overall 626 (100)
Year
2009 137 (21.9)
2010 118 (18.8)
2011 141 (22.5)
2012 125 (20.0)
2013 105 (16.8)
Missing 0 (0.0)
Sex
Male 380 (60.7)
Female 246 (39.3)
Missing 0 (0.0)
Age years
18–37 358 (57.2)
38–57 199 (31.8)
58–77 62 (9.9)
⩾78 7 (1.1)
Missing 0 (0.0)
UK born
No 497 (79.4)
Yes 121 (19.3)
Missing 8 (1.3)
Ethnic group
White 97 (15.5)
Black African 125 (20.0)
Black Other 45 (7.2)
Indian subcontinent 270 (43.1)
Other 85 (13.6)
Missing 4 (0.6)
Social risk factors
No or unknown 510 (81.5)
One or more ever 37 (5.9)
One or more current 79 (12.6)
Previous TB diagnosis
No 575 (91.9)
Yes 20 (3.2)
Missing 31 (5.0)
Inpatient
No 422 (67.4)
Yes 190 (30.4)
Missing 14 (2.2)
Site of disease
Pulmonary±extrapulmonary, smear +ve 194 (31.0)
Pulmonary±extrapulmonary, smear –ve 159 (25.4)
Meningeal TB or other CNS involvement 24 (3.8)
Other extrapulmonary 249 (39.8)
Missing 0 (0.0)
Part of outbreak
No 501 (80.0)
Yes 65 (10.4)
Missing 60 (9.6)
Any additional drug resistance
No 453 (72.4)
Yes 173 (27.6)
Data are presented as n (column %). TB: tuberculosis; CNS: central nervous system; ±: with or without;
−ve: negative; +ve: positive.
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had only a single patient and was not approached for local approvals. The baseline characteristics of the
London cohort are described in table 2.
Phenotypic testing for non-H drug resistance revealed that 173 (27.6%) out of 626 patients within the
London cohort had additional drug resistance at baseline (supplementary file 3). The most common
resistance was towards S (139 (22.2%) out of 626).
The majority of samples were documented in the NMRS system as highly Hr at baseline (495 (79.1%) out
of 626). Three (0.5%) displayed borderline results; one was listed as drug sensitive (0.2%); and 35 (5.6%)
were present in the system, but did not have their Hr levels logged. 47 individuals could not be found
within NMRS, but were recorded as Hr within ETS.
Regimen-specific outcomes
Regimen-specific outcomes were available for 592 (94.6%) out of 626 patients (table 3). 97 (16.4%) had a
negative outcome.
Relationship between treatment regimens and regimen-specific outcomes
Of the 626 patients, 582 (93.0%) had both a regimen-specific outcome recorded and treatment
information. Of these, 538 (92.4%) were not resistant to drugs in addition to H, apart from S, and 84 had
a negative regimen-specific outcome (three of which were recurrences). 498 (92.6%) out of 538 were
treated with (H)RfZE or (H)RfZE-Fq/M (table 4). For a more detailed description of the treatment
regimens, see supplementary file 4.
Differences in the odds of a negative regimen-specific outcome were not detected between patients treated
with (H)RfZE (baseline) and (H)RfZE-Fq/M (cluster-specific OR 1.02, 95% CI 0.59–1.77; p=0.93; table 4).
None of the other treatment regimens or associated factors were found to be associated with the odds of
negative outcomes (table 4, supplementary file 5). We observed more negative outcomes with the use of
thrice weekly dosing versus more frequent dosing (OR 1.81, 95% CI 0.83–3.94), but this may have been a
chance finding (p=0.15).
Seven exposure variables/confounders were included in the multivariable model: regimen, thrice-weekly
dosing, Hr phenotype, sex, age (linear variable), ethnic group and previous TB diagnosis. Evidence for
effect modification was not found. In the final multivariable model of 435 patients (table 5), there was no
TABLE 3 Regimen-specific outcomes and availability of regimen data
Negative Neutral Positive
Frequency of outcome
n (% of 592)
97 (16.4) 87 (14.7) 408 (68.9)
Details of outcome n=3 recurrences after treatment was completed
n=2 recurrences after an otherwise neutral or missing
outcome
n=3 developed additional drug resistance (two to R and one
to clarithromycin; additionally, one patient developed
resistance to E and one to R, but this was predated by
other negative outcomes)
n=1 stopped treatment for negative reasons
n=7 had the length of their treatment extended for
negative reasons
n=78 treatment regimen changes by other means for
negative reasons
n=3 deaths from TB >2 weeks after treatment started
Regimen data
available n (column
% within outcome)
95 (97.9) 79 (90.8) 408 (100.0)
Details of regimen
data
n=374 with regimen data for the full
duration of treatment
n=7 partial uncertainties surrounding
the drugs present in the regimen
n=27 some date information missing
Regimen-specific outcomes and treatment regimen availability for the 592 (94.6%) out of 626 of individuals with an outcome recorded in the
London cohort. E: ethambutol; R: rifampicin; TB: tuberculosis.
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discernible difference in the odds of a negative outcome between the two regimens (OR 0.99, 95% CI
0.53–1.85; p=0.97). The association between thrice-weekly dosing and negative outcomes was slightly
strengthened in terms of the effect estimate (OR 2.34, 95% CI (0.90–6.09), although the association
observed could still have been due to chance (p=0.09).
Impact of genotype and other sensitivity analyses
The most common Hr genotypes observed were fabG1 C-15 T (87 (50.9%) out of 171) and katG S315 T
(75 (43.9%) out of 171; supplementary file 6). For 10 (5.8%) out of 171 strains, sequencing either failed,
no resistance mutations were detected or it was not known whether the single nucleotide polymorphisms
(SNPs) found generate drug resistance.
In a univariable model, no difference was seen in the likelihood of a negative treatment outcome between
the katG S315 T/N genotypes and a fabG1 C-15 T baseline (OR 1.17, 95% CI 0.42–3.31; p=0.76). In a
multivariable model, evidence for effect modification by genotype was not detected. Genotype was not
independently associated with the outcome (supplementary file 7). In this model, there was a suggestion
that the odds of a negative regimen-specific outcome were reduced for (H)RfZE-Fq/M versus (H)RfZE
(OR 0.57, 95% CI 0.14–2.28), but we were underpowered for this analysis (p=0.42).
Inclusion of other potential confounder sets in the multivariable model did not impact our findings
(supplementary file 8).
Discussion
In this analysis of Hr TB patients notified by London hospitals between 2009 and 2013, 16.4% of
individuals had a negative outcome. (H)RfZE and (H)RfZE-Fq/M regimens were taken by 92.6% of
individuals without additional drug resistance (apart from to S) and with both regimen and
regimen-specific outcome data. Among these patients, we found no discernible difference in the odds of a
negative regimen-specific outcome between (H)RfZE and (H)RfZE-Fq/M regimens. Examining individuals
TABLE 4 Univariable logistic regression of treatment regimen and associated factors as
predictors of negative outcomes
Overall n
(column %)
Negative outcome
n (row %)
OR (95% CI) p-value
Overall 538 (100) 84 (15.6)
Regimen
(H)RfZE 306 (56.9) 46 (15.0) 0.93
(H)RfZE-Fq/M 192 (35.7) 30 (15.6) 1.02 (0.59–1.77)
Missing 40 (7.4) 8 (20.0)
Thrice-weekly dosing
More frequent 464 (86.2) 66 (14.2) 0.15
Thrice weekly 53 (9.9) 12 (22.6) 1.81 (0.83–3.94)
Missing 21 (3.9) 6 (28.6)
Time before Hr known
0 to <2 months 325 (60.4) 56 (17.2) 0.27
2 to <6 months 159 (29.6) 18 (11.3) 0.62 (0.34–1.13)
⩾6 months 10 (1.9) 2 (20.0) 1.11 (0.22–5.66)
Missing 44 (8.2) 8 (18.2)
Phenotype
Highly resistant 442 (82.2) 69 (15.6) 0.73
Resistant 36 (6.7) 5 (13.9) 0.88 (0.32–2.39)
Borderline, sensitive or results not logged 29 (5.4) 6 (20.7) 1.46 (0.55–3.88)
Missing 31 (5.8) 4 (12.9)
Adherence issues or treatment gaps
No or unknown 425 (79.0) 64 (15.1) 0.29
Not severe or of unknown severity 56 (10.4) 13 (23.2) 1.62 (0.80–3.28)
Severe 57 (10.6) 7 (12.3) 0.72 (0.30–1.73)
Univariable logistic regression of treatment regimen and associated factors as predictors of negative
regimen-specific outcomes. Included patients were notified in London, had regimen-specific outcome and
regimen information, and their disease was without additional drug resistance, unless to streptomycin.
Each model contains the patients without missing data. H: isoniazid; Rf: rifamycin; Z: pyrazinamide;
E: ethambutol; Fq: fluoroquinolones; M: moxifloxacin; Hr: isoniazid resistance.
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with a positive treatment outcome, the overall duration of treatment was generally 12 months, with Z
durations of 2 months in the initiation phase. After adjustment for Hr genotype, the likelihood of a
negative outcome was found to be lower among individuals treated with (H)RfZE-Fq/M, but this analysis
was underpowered.
Our findings sit in the context of preceding work on the relative efficacy and effectiveness of different
regimens for Hr TB, including four meta-analyses [17–20]. FREGONESE et al.’s [17] individual-level patient
meta-analysis, the foundation of the 2018 WHO guidelines, showed a value for including a Fq in
continuous (H)RZE regimens, and suggested equivalence between 6 and 8–9 months of (H)RZE. The
WHO acknowledges that overall treatment length findings may be subject to confounding by indication,
due to patients with more complex sites of disease receiving longer regimens [5].
Notably, global RCT evidence for the effectiveness of Fqs in non-MDR-TB derive solely from the Rifaquin
trial, as ReMox did not demonstrate non-inferiority when H was replaced with M for non-MDR TB [21, 22].
When considering the choice of Fq, although the WHO recommends the use of Lfx, M was generally used in
our study. Within FREGONESE et al. [17], roughly equal numbers of studies used these two drugs, which were
not directly compared. However, comparative data are available from a MDR-TB trial (no difference in
treatment outcomes when comparing the two drugs; fewer adverse events for M) [23], and rabbit and mouse
models (M broadly superior over Lfx) [24, 25]. Lfx doses in such studies may have been too low [26, 27].
Further RCTs are required.
The above meta-analyses were unable to thoroughly consider the role of Hr genotype and phenotype in
treatment decisions; the evidence from previous observational studies is unclear [1, 28]. Where adjustment
for genotype in observational studies has been undertaken, it was largely for inhA and katG. In our cohort,
with a very high prevalence of fabG1 in addition to katG mutations, we find an indication that the Hr
genotype is influential. fabG1 is part of the inhA operon and is involved in fatty acid synthesis; SNPs
within the gene are known to confer Hr [29, 30].
TABLE 5 Multivariable logistic regression of treatment regimen as a predictor of negative
outcomes
OR (95% CI) p-value
Regimen
(H)RfZE 0.97
(H)RfZE-Fq/M 0.99 (0.53–1.85)
Thrice-weekly dosing
More frequent 0.09
Thrice weekly 2.34 (0.90–6.09)
Phenotype
Highly resistant 0.66
Resistant 0.64 (0.17–2.43)
Borderline, sensitive or results not logged 1.40 (0.45–4.31)
Missing
Sex
Male 0.02
Female 2.05 (1.13–3.71)
Age years
18–37 0.46
Per 20-year increase 1.18 (0.75–1.86)
Ethnic group
White 0.15
Black African 0.42 (0.15–1.18)
Black Other 0.33 (0.08–1.39)
Indian subcontinent 0.58 (0.23–1.45)
Other 1.10 (0.42–2.92)
Previous TB diagnosis
No 0.13
Yes 3.12 (0.75–12.91)
Multivariable logistic regression of treatment regimen as a predictor of negative regimen-specific
outcomes in patients without additional drug resistance, unless to streptomycin, adjusted for all variables
in the table. Model contains 435 patients. H: isoniazid; Rf: rifamycin; Z: pyrazinamide; E: ethambutol;
Fq: fluoroquinolones; M: moxifloxacin; TB: tuberculosis.
https://doi.org/10.1183/13993003.00982-2019 8
TUBERCULOSIS | H.R. STAGG ET AL.
The evidence currently underpinning global treatment guidelines for Hr TB is limited. Our study adds to
this discussion, including consideration of the effect of resistance phenotype and genotype on the
regimen–outcomes relationship. Importantly, in our core analysis, 192 patients received a Fq in addition to
(H)RfZE, which provides substantial new evidence to that presented by FREGONESE et al. [17], whose
analysis of treatment success included 251 patients receiving a Fq. Our findings did not differ when site of
disease was adjusted for as a confounder (including meningeal TB or other central nervous system
involvement; data not shown) and when patients with additional drug resistance were included.
Within this study, actual rather than intended treatment durations were captured, which prevented us from
undertaking analyses of the impact of overall or drug-specific durations. Importantly, however, when
considering 9 versus 12 months of treatment, the majority of negative outcomes occurred before 9 months
and the number of relapses was small, with two of the three occurring after >15 months of treatment. Thus
our data may indicate the potential to shorten treatment to 9 months in our setting. Some patient notes
could not be accessed as patients had died. This was unlikely to have been of a magnitude sufficient to bias
our findings. We did not differentiate between recurrence due to relapse versus reinfection, and thus may
have overestimated the number of negative outcomes (nondifferential misclassification). Gaps in phenotypic
data arose due to 1) missing records within NMRS from a specific period and reference laboratory; and 2)
incomplete data entry into NMRS from the reference laboratory (cross-tabulations against patient
characteristics did not indicate that this particularly affected any specific patient groups). The phenotypic
and genotypic Hr patterns documented summarise that of the overall bacterial population; the presence of
minor strains will not have been captured. Our findings about thrice-weekly dosing may represent the use
of such a dosing pattern specifically among patients where directed observation of treatment was deemed
necessary. HIV status, a potential confounder, was not obtainable during data collection.
Despite these limitations, there are important ramifications for our findings both nationally and
internationally. We document a drug combination that differs from that recommended (with very low
certainty) by the WHO [5], which may be as effective. We note that, if the overall duration of treatment is
long enough (12 months), a Fq may not be necessary in certain settings, even with relatively short
durations (median 2 months in the initiation phase) of Z. Notably, in settings where DST occurs via
phenotyping from cultures, the WHO regimen ⩾6[H]RZE-6Lfx is likely to have total duration of
7.5–9 months, when time to result is considered. This also affects the longer regimen in their 6- versus
8–9-month duration comparison; the latter translates to 9.5–12 months. By comparison, in settings
undertaking rapid genotyping directly from patient samples, the WHO regimen duration would be
6 months and the average duration documented here ∼10 months.
Global regimen choices will depend upon the trade-off between patient desire for regimens of minimal
length, adherence concerns, adverse events, ease of administration and cost. Costs are raised if fixed dose
combination pills cannot be used and Fqs are added in. When it comes to comparing the likelihood of
adverse events, the trade-off would be between a longer duration of E, but shorter duration of Z in our
predominantly used regimen, versus continued Z and the addition of LfX, as per the WHO
recommendations. Each of these drugs has its own distinct adverse event profile [23, 31].
Fq DST results are important when deciding on Fq use within a Hr regimen. Only 48 individuals in the
London cohort had their baseline samples tested for resistance to M. In 2018, PHE rolled-out prospective
WGS to provide routine resistance predictions and mutation identification, thus improving the rapidity of
DST and coverage of second-line testing. New molecular Hr tests can also aid rapidity, as the use of WGS
still depends on culture [32].
Within the limitations of an observational study, where the use of Fqs was not randomised, we find in a
high-income setting with comprehensive patient management, a 12-month (H)RfZE regimen with a short
Z duration to be similarly effective for Hr TB, with or without a Fq. Hr genotype may influence these
findings. In the absence of Fqs and long durations of Z, this regimen may have fewer adverse events than
the WHO recommended ⩾6[H]RZE-6Lfx. RCTs should be undertaken to provide stronger global
recommendations.
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